These data confirm that PD1-IL2v as monotherapy is more efficacious than the combination of pembrolizumab with high-dose aldesleukin, that PD1-IL2v does not require additional PD-1 blockade to increase its efficacy in this tumour model at the tested doses and that CD8+ TILs express roughly 20-fold more PD-1 receptors per T cell than CD8+ T cells in the blood, supporting the rationale for a tumour-preferential effect of PD1-IL2v. This evidence concerns the gene PDCD1 and neoplasm.